Surgical Treatment of High Perianal Fistulas (LIFTRAF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01997645 |
Recruitment Status : Unknown
Verified November 2013 by Otakar Sotona, University Hospital Hradec Kralove.
Recruitment status was: Recruiting
First Posted : November 28, 2013
Last Update Posted : November 28, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Perianal fistula is a chronic phase of anorectal infection that occurs predominantly in the third and fourth decade of life. According to Parks classification fistulas have been divided into intersphincteric, transsphincteric, suprasphincteric and extrasphincteric. Simple fistulotomy can be performed with satisfactory outcomes in low fistula tracts but in high (transsphincteric) fistulas it may affect anal continence seriously.
Therefore sphincter preserving procedures should be preferred in these cases. Rectal advancement mucosal flap (RAF) is one of the methods used in surgical fistula eradication with high success rate in cryptoglandular fistulas. However, this technique is technically demanding and results can be expert depended with wide spread of healing rates (24-100%) in individual studies as referred in recent systematic review.
Ligation of the intersphincteric fistula tract (LIFT) has been presented in 2007 as a simple sphincter preserving technique. The success rate varies between 40-95% with low overall incontinence rate (6%).
The aim of the study is to compare the efficacy of the LIFT and RAF procedure for treatment of high perianal fistulas.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anal Fistula Rectal Fistula | Procedure: LIFT Procedure: RAF | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Ligation of Intersphincteric Fistula Tract (LIFT) Versus Rectal Advanced Mucosal Flap (RAF) in Surgical Treatment of High Perianal Fistulas |
Study Start Date : | November 2013 |
Estimated Primary Completion Date : | June 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Rectal advanced mucosal flap
Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery. In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open. |
Procedure: RAF |
Active Comparator: Ligation of intersphincteric fistula tract
Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery. Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain. |
Procedure: LIFT |
- Recurrence rate [ Time Frame: One year ]
Fistula recurrence will be defined according to AGA (American Gastroenterological Association) criteria as a purulent secretion from external fistula opening followed the compression.
Fistula recurrence will be confirmed by evaluation under anesthesia (followed by drainage).
- Postoperative pain [ Time Frame: 14 days ]Postoperative pain will be assessed 4 times per day during the first 2 postoperative days (VAS - visual analogue scale), after that 3 times per day over next 14 days (patient's diary).
- Pre- and postoperative continence [ Time Frame: One year ]Pre- and postoperative continence will be evaluated with Wexner score.
- Postoperative morbidity [ Time Frame: One month ]Will be evaluated according to Clavien-Dindo classification.
- Quality of life [ Time Frame: One year ]For quality of life evaluation SF-36 questionnaire will be used.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients aged 18 years old or older
- Diagnosis of simple intersphincteric or transsphincteric fistula
- Patients able to comply with the study protocol as per investigator criteria
- Signed and dated informed consent by the patient
- Absence of any exclusion criteria
Exclusion Criteria:
- Recurrent anal fistula
- Suprasphincteric, low subcutaneous fistula
- Multiple fistulas
- Posttraumatic fistula
- Perianal hidradenitis
- Fistula arises from other than cryptoglandular origin
- Previous anal surgery except of abscess
- Inflammatory Bowel Disease
- History of fecal incontinence
- Rectal prolapse
- Malignant disease and life expectancy of less than 1 year, or chemotherapy and radiotherapy less than six months prior enrolment
- HIV infection
- Pregnancy
- Participation in another clinical trial less than one month prior to enrolment, or involvement in another trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01997645
Contact: Július Örhalmi, MD | +420606506391 | orhalmi@volny.cz |
Czech Republic | |
Department of Surgery, Charles University, Faculty of Medicine and University Hospital | Recruiting |
Hradec Kralove, Czech Republic, 50005 | |
Contact: Július Örhalmi, MD +420606506391 orhalmi@volny.cz | |
Principal Investigator: Július Örhalmi, MD | |
Departement of Surgery, District Hospital | Recruiting |
Novy Jicin, Czech Republic, 74101 | |
Contact: Karel Klos, MD +420602412096 kajaanek@gmail.com | |
Principal Investigator: Karel Klos, MD | |
Departement of Surgery, Military University Hospital | Recruiting |
Prague, Czech Republic, 16902 | |
Contact: Zuzana Šerclová, MD +420602158805 sercl@seznam.cz | |
Principal Investigator: Zuzana Šerclová, MD |
Principal Investigator: | Július Örhalmi, MD | University Hospital Hradec Kralove | |
Principal Investigator: | Zuzana Šerclová, MD | Central MIlitary Hospital Prague | |
Principal Investigator: | Karel Klos, MD | District Hospital Nový Jičín |
Responsible Party: | Otakar Sotona, MD, University Hospital Hradec Kralove |
ClinicalTrials.gov Identifier: | NCT01997645 |
Other Study ID Numbers: |
FN HK CP 2013 |
First Posted: | November 28, 2013 Key Record Dates |
Last Update Posted: | November 28, 2013 |
Last Verified: | November 2013 |
Anal fistula Rectal fistula Intersphincteric fistula Perianal fistula |
Rectal Fistula Fistula Pathological Conditions, Anatomical Intestinal Fistula Digestive System Fistula |
Digestive System Diseases Intestinal Diseases Gastrointestinal Diseases Rectal Diseases |